Freeline Therapeutics Holdings Stock Price To Sales
| FRLNDelisted Stock | USD 4.31 0.28 6.10% |
Freeline Therapeutics Holdings fundamentals help investors to digest information that contributes to Freeline Therapeutics' financial success or failures. It also enables traders to predict the movement of Freeline Stock. The fundamental analysis module provides a way to measure Freeline Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Freeline Therapeutics stock.
Freeline |
Freeline Therapeutics Holdings Company Price To Sales Analysis
Freeline Therapeutics' Price to Sales ratio is typically used for valuing equity relative to its own past performance as well as to performance of other companies or market indexes. In most cases, the lower the ratio, the better it is for investors. However, it is advisable for investors to exercise caution when looking at price-to-sales ratios across different industries.
Current Freeline Therapeutics Price To Sales | 45.40 X |
Most of Freeline Therapeutics' fundamental indicators, such as Price To Sales, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Freeline Therapeutics Holdings is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
The most critical factor to remember is that the price of equity takes a firm's debt into account, whereas the sales indicators do not consider financial leverage. Generally speaking, Price to Sales ratio shows how much market values every dollar of the company's sales.
CompetitionBased on the latest financial disclosure, Freeline Therapeutics Holdings has a Price To Sales of 45.4012 times. This is 112.16% higher than that of the Biotechnology sector and 53.87% lower than that of the Health Care industry. The price to sales for all United States stocks is notably lower than that of the firm.
Freeline Price To Sales Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Freeline Therapeutics' direct or indirect competition against its Price To Sales to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Freeline Therapeutics could also be used in its relative valuation, which is a method of valuing Freeline Therapeutics by comparing valuation metrics of similar companies.Freeline Therapeutics is currently under evaluation in price to sales category among its peers.
Freeline Fundamentals
| Return On Equity | -1.01 | |||
| Return On Asset | -0.56 | |||
| Current Valuation | 2.78 M | |||
| Shares Outstanding | 4.36 M | |||
| Shares Owned By Insiders | 1.09 % | |||
| Shares Owned By Institutions | 45.88 % | |||
| Number Of Shares Shorted | 23.93 K | |||
| Price To Book | 0.94 X | |||
| Price To Sales | 45.40 X | |||
| Revenue | 622 K | |||
| EBITDA | (64.84 M) | |||
| Net Income | (49.93 M) | |||
| Cash And Equivalents | 90 M | |||
| Cash Per Share | 1.38 X | |||
| Total Debt | 5.92 M | |||
| Debt To Equity | 0.64 % | |||
| Current Ratio | 3.68 X | |||
| Book Value Per Share | 6.89 X | |||
| Cash Flow From Operations | (64.24 M) | |||
| Short Ratio | 1.92 X | |||
| Earnings Per Share | (11.40) X | |||
| Target Price | 8.25 | |||
| Number Of Employees | 152 | |||
| Beta | 0.66 | |||
| Market Capitalization | 28.24 M | |||
| Total Asset | 86.64 M | |||
| Retained Earnings | (445.35 M) | |||
| Working Capital | 36.66 M | |||
| Z Score | -6.29 | |||
| Net Asset | 86.64 M |
About Freeline Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Freeline Therapeutics Holdings's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Freeline Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Freeline Therapeutics Holdings based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Freeline Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Freeline Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Freeline Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving against Freeline Stock
| 0.7 | MCD | McDonalds Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.64 | IBM | International Business Fiscal Year End 22nd of January 2025 | PairCorr |
| 0.56 | CAT | Caterpillar Fiscal Year End 3rd of February 2025 | PairCorr |
| 0.35 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.34 | AA | Alcoa Corp Fiscal Year End 15th of January 2025 | PairCorr |
The ability to find closely correlated positions to Freeline Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Freeline Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Freeline Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Freeline Therapeutics Holdings to buy it.
The correlation of Freeline Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Freeline Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Freeline Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Freeline Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis. You can also try the Idea Analyzer module to analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas.
Other Consideration for investing in Freeline Stock
If you are still planning to invest in Freeline Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Freeline Therapeutics' history and understand the potential risks before investing.
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Stocks Directory Find actively traded stocks across global markets | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance |